MW ADVISORY, LLC’s AbbVie ABBV Stock Holding History

MW ADVISORY, LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Buy	+4,154	New	+$894K	0.42%	48

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

MW ADVISORY, LLC's ABBV Position: Q2 2026 in Review

MW ADVISORY, LLC opened a new position in AbbVie (ABBV) in Q2 2026: 4,154 shares worth $1.05M. The stake represents 0.42% of the portfolio and ranks #48 among its holdings.

2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

MW ADVISORY, LLC held 4,154 shares of AbbVie worth $1.05M as of Q2 2026.
AbbVie was a new MW ADVISORY, LLC position in Q2 2026.
AbbVie made up 0.42% of MW ADVISORY, LLC's portfolio in Q2 2026, its #48 holding.
2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on MW ADVISORY, LLC's 13F filing for Q2 2026, filed 7 Aug 2026.